The stock of GenMark Diagnostics, Inc (NASDAQ:GNMK) is a huge mover today! About 147,952 shares traded hands. GenMark Diagnostics, Inc (NASDAQ:GNMK) has risen 135.33% since March 8, 2016 and is uptrending. It has outperformed by 126.01% the S&P500.
The move comes after 8 months negative chart setup for the $546.14M company. It was reported on Oct, 11 by Barchart.com. We have $11.27 PT which if reached, will make NASDAQ:GNMK worth $49.15 million less.
Analysts await GenMark Diagnostics, Inc (NASDAQ:GNMK) to report earnings on October, 25. They expect $-0.31 earnings per share, down 14.81% or $0.04 from last year’s $-0.27 per share. After $-0.30 actual earnings per share reported by GenMark Diagnostics, Inc for the previous quarter, Wall Street now forecasts 3.33% negative EPS growth.
GenMark Diagnostics, Inc (NASDAQ:GNMK) Ratings Coverage
Out of 3 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genmark Diagnostics has been the topic of 5 analyst reports since October 14, 2015 according to StockzIntelligence Inc. Cowen & Co upgraded the shares of GNMK in a report on Friday, September 16 to “Outperform” rating. The firm has “Buy” rating by Needham given on Wednesday, October 28. The rating was maintained by Needham on Wednesday, February 24 with “Buy”.
According to Zacks Investment Research, “GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensorÂ® XT-8 system is the second generation in GenMark Dx’s eSensorÂ® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0.91 in 2016 Q2. Its down 0.50, from 1.41 in 2016Q1. The ratio fall, as 11 funds sold all GenMark Diagnostics, Inc shares owned while 23 reduced positions. 3 funds bought stakes while 28 increased positions. They now own 43.35 million shares or 1.06% less from 43.82 million shares in 2016Q1.
Morgan Stanley owns 1.95M shares or 0.01% of their US portfolio. Fmr Limited Liability has 6.42M shares for 0.01% of their US portfolio. Wells Fargo And Mn owns 24,042 shares or 0% of their US portfolio. Schwab Charles Mgmt Inc has 149,145 shares for 0% of their US portfolio. Jpmorgan Chase & reported 3.01 million shares or 0.01% of all its holdings. The Indiana-based Donaldson Cap Mngmt Limited Company has invested 0.08% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Credit Suisse Ag has 37,034 shares for 0% of their US portfolio. Artemis Inv Management Llp accumulated 0.03% or 216,928 shares. State Board Of Administration Of Florida Retirement System has 17,007 shares for 0% of their US portfolio. State Street Corp holds 644,349 shares or 0% of its portfolio. Blackrock Institutional Trust Na has 0% invested in the company for 717,276 shares. Cannell Peter B & Com has invested 0% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK). Teachers Advisors has 92,374 shares for 0% of their US portfolio. Rmb Management Ltd Company owns 1.16M shares or 0.53% of their US portfolio. Moreover, Royal Commercial Bank Of Canada has 0% invested in GenMark Diagnostics, Inc (NASDAQ:GNMK) for 1,356 shares.
Insider Transactions: Since May 9, 2016, the stock had 1 buy, and 24 insider sales for $416,178 net activity. Gleeson Michael sold $7,640 worth of stock or 868 shares. Stier Eric also sold $3,626 worth of GenMark Diagnostics, Inc (NASDAQ:GNMK) shares. $51,627 worth of GenMark Diagnostics, Inc (NASDAQ:GNMK) was sold by Williams Jennifer Anne on Wednesday, August 17. The insider Kayyem Jon Faiz sold $2,694. Another trade for 1,188 shares valued at $10,668 was sold by MASSARANY HANY. On Friday, August 12 Giles Lisa M. bought $7,736 worth of the stock or 823 shares. Chakravarty Ingo also sold $1,570 worth of GenMark Diagnostics, Inc (NASDAQ:GNMK) shares.
More recent GenMark Diagnostics, Inc (NASDAQ:GNMK) news were published by: Fool.com which released: “Why GenMark Diagnostics, Inc. Is Soaring Today” on September 16, 2016. Also Quotes.Wsj.com published the news titled: “News GenMark Diagnostics Inc.GNMK” on February 11, 2011. Seekingalpha.com‘s news article titled: “GenMark Diagnostics Is A Worthy Fourth-Quarter Buying Opportunity” with publication date: August 26, 2016 was also an interesting one.
GNMK Company Profile
GenMark Diagnostics, Inc. (GenMark), incorporated on February 12, 2010, is a molecular diagnostics company. The Firm focuses on developing and commercializing its eSensor detection technology. The Company’s eSensor electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Firm sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. In addition, it has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. The Company’s XT-8 system supports approximately 20 independent test cartridges. It has an installed base of over 630 XT-8 analyzers, or placements, with its customers. It has a menu of approximately eight tests for use with its XT-8 system. Approximately four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.